A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors

Autor:	C. Okereke, Anthony B. El-Khoueiry, T. Goldberg, P. Conti, K. Feit, D. P. Rossignol, I. Krivelevich, Syma Iqbal, H. J. Lenz
Rok vydání:	2008
Předmět:	Tube formation Cancer Research Cetuximab business.industry In vitro Phase i study Endothelial stem cell Oncology Maximum tolerated dose Cancer research medicine Single agent In patient business medicine.drug
Zdroj:	Journal of Clinical Oncology. 26:3568-3568
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2008.26.15_suppl.3568
Popis:	3568 Background: In vitro, E7820 inhibits α2-integrin expression, endothelial cell proliferation and vascular tube formation. The maximum tolerated dose (MTD) of E7820 as a single agent is 100mg/da...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d7d86cbfce17f2d6f110a87f29fa8ef5 https://doi.org/10.1200/jco.2008.26.15_suppl.3568 Zobrazit plný text záznamu